PaxMedica (MEX:PXMD) Tariff Resilience Score: 0/10 (As of Jul. 04, 2026)


MEX:PXMD PaxMedica Inc MEX:PXMD
20 GF Score
Price MXN15.69
View Full Analysis

What is PaxMedica Tariff Resilience Score?

PaxMedica has the Tariff Resilience Score of 0, which implies that the company might have .

PaxMedica has PaxMedica's pharmaceutical focus means moderate exposure to tariffs, primarily through raw material imports. The company has limited pricing power but can leverage alternative suppliers. The industry has some exemptions, but past tariffs have affected costs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes PaxMedica might have .

PaxMedica  (MEX:PXMD) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

PaxMedica Tariff Resilience Score Related Terms

MEX:PXMD
20GF Score
PaxMedica Inc MEX:PXMD
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PaxMedica Business Description

Address 303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
20GF Score

Get the complete analysis for MEX:PXMD

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN15.69
Price